PropThink: TH-302 Development: In the Shadow of the Competition

2012-11-15 17:47:54 -

By Jake King



After declines in the first half of the week, shares of Threshold

Pharmaceuticals (NASDAQ:THLD) rebounded on Thursday morning following an update

on the company's ongoing Phase 2 trial of TH-302 (403 Trial) in soft tissue

sarcoma. The drug in combination with doxorubicin demonstrated a median

progression free survival (PFS) of 6.7 months, a median overall survival (OS) of

21.5 months, and an acceptable safety profile. In a single-arm component of the

study (roughly half of the total patient population) patients continued

treatment with TH-302 as a single agent following the doxorubicin combination

treatment; median PFS was 3.7 months, and median OS was 18.0 months in the

maintenance extension. The Phase 2 supports the ongoing Phase 3 '406 Trial', in

which TH-302 plus doxorubicin is being compared to doxorubicin alone as a first-

line soft tissue sarcoma treatment; interim data is expected in 1H13. That trial

is being carried out under a Special Protocol Assessment with the FDA.



Threshold, however, bears the brunt of upcoming trial results from multiple

competitors. Continue reading here.



Click here to see the full article at PropThink.com.



About PropThink



PropThink is an intelligence service that delivers long and short trading ideas

to investors in the healthcare and life sciences sectors. Our focus is on

identifying and analyzing technically-complicated companies and equities that

are grossly over or under-valued. We offer daily market coverage, weekly feature

stories, and a newsletter to investors who subscribe on PropThink.com. To learn

more, follow us on Twitter or visit us at  www.propthink.com.



Disclaimer:



You should assume that as of the publication date of any report or letter,

PropThink, LLC and persons or entities with whom it has relation ships

(collectively referred to as "PropThink") has a position in all stocks (and/or

options of the stock) covered herein that is consistent with the position set

forth in our research report. Following publication of any report or

letter, PropThink intends to continue transacting in the securities covered

herein, and we may be long, short, or neutral at any time hereafter regardless

of our initial recommendation. To the best of our knowledge and belief, all

information contained herein is accurate and reliable, and has been obtained

from public sources we believe to be accurate and reliable, and not from company

insiders or persons who have a relationship with company insiders. PropThink was

not compensated to publish this article. Our full disclaimer is available

at  www.propthink.com/disclaimer.









This announcement is distributed by Thomson Reuters on behalf of 

Thomson Reuters clients. The owner of this announcement warrants that: 

(i) the releases contained herein are protected by copyright and 

    other applicable laws; and 

(ii) they are solely responsible for the content, accuracy and 

     originality of the information contained therein. 

    

Source: PropThink via Thomson Reuters ONE

[HUG#1658555]